3%高渗盐水联合吸入用复方异丙托溴铵溶液雾化吸入治疗呼吸道合胞病毒肺炎的效果

Abstract
Figure/Table
References (19)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of 3% hypertonic saline combined with Compound Ipratropium Bromide Solution atomization inhalation in the treatment of respiratory syncytial virus pneumonia. Methods A total of 195 children with respiratory syncytial virus pneumonia who were treated in People′s Hospital of Yichun City, Jiangxi Province from January 2015 to December 2016 were selected as the research subjects. According to the random number table method,they were divided into treatment group 1(65 cases),treatment group 2 (65 cases) and treatment group 3 (65 cases). The treatment group 1 received 3% hypertonic saline 4 mL + Compound Ipratropium Bromide Solution atomized inhalation. The treatment group 2 was treated with 4 mL of normal saline + Compound Ipratropium Bromide Solution atomized inhalation. The treatment group 3 was treated with 0.9% sodium chloride solution 2 mL + Terbutaline Sulfate Atomized Solution + Budesonide Suspension atomized inhalation. The time of cough disappearance, shortness of breath disappearance, asthma disappearance, lung signs disappearance, hospital stay and treatment effect of the three groups were compared. Results The disappearance time of cough, shortness of breath, dyspnea, lung signs and hospitalization time in treatment group 1 were shorter than those in treatment group 2 and treatment group 3, with statistical significances (P＜0.05). However, there were no significant differences in the disappearance time of cough, shortness of breath,dyspnea, lung signs and hospitalization time between the treatment group 2 and treatment group 3 (P＞0.05). The total effective rate of treatment group 1 was higher than that of treatment group 2 and treatment group 3, and the difference was statistically significant (P＜0.05). However, there was no significant difference in the total effective rate between the treatment group 2 and treatment group 3 (P＞0.05). Conclusion 3% hypertonic saline combined with Compound Ipratropium Bromide Solution atomization inhalation in the treatment of respiratory syncytial virus pneumonia has a high cure rate, which can relieve cough, shortness of breath, shortness of breath, lung signs and shorten the duration of hospitalization as soon as possible. It′s worth popularizing.

Key words： 3% hypertonic saline Respiratory syncytial virus Pneumonia Inhalation with Compound Ipratropium Bromide Solution

Received: 02 November 2020

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I12/115

[1]	陈红燕.普米克令舒和可必特雾化吸入治疗哮喘性支气管炎[J].安徽卫生职业技术学院学报，2020，19（1）：49-50.
[2]	高占成，胡大一.呼吸内科[M].北京：北京科学技术出版社，2010：312.
[3]	杨文凤，黄善周，植旭丽.雾化吸入干扰素治疗呼吸道合胞病毒性肺炎的疗效[J].深圳中西医结合杂志，2020，30（18）：164-165.
[4]	张欣.丙酸倍氯米松联合可必特对小儿支气管肺炎的作用[J].中国城乡企业卫生，2020，35（3）：148-150.
[5]	董焕远，尹志平，欧阳明超.可必特与博利康尼治疗AECOPD 的疗效比较[J].北方药学，2020，17（3）：33-34.
[6]	谢彤，杜丽娜，徐建亚，等.基于脂质代谢网络的虎杖抗呼吸道合胞病毒肺炎代谢组学研究[J].世界中医药，2016，11（9）：1670-1673.
[7]	刘学术.普米克、可必特雾化吸入治疗小儿哮喘的疗效分析[J].中西医结合心血管病电子杂志，2020，8（3）：92.
[8]	龚厚玲，张玉兰.沙丁胺醇气动雾化吸入治疗小儿支气管哮喘急性发作期的效果观察[J].当代医学，2020，26（30）：157-158.
[9]	徐宝恒.可必特与普米克令舒治疗哮喘性支气管炎的临床疗效分析[J].中国实用医药，2019，14（36）：83-85.
[10]	张莹，王秀琼.可必特治疗慢性阻塞肺疾病急性发作的临床疗效[J].黑龙江医药，2019，32（6）：1328-1330.
[11]	王国庆.无创通气与普米克令舒加可必特雾化治疗慢阻肺并呼吸衰竭的研究[J].中国社区医师，2019，35（36）：91，93.
[12]	程鑫.普米克令舒和可必特雾化吸入治疗哮喘性支气管炎的临床价值研究[J].中国医药指南，2019，17（33）：149.
[13]	黄立君.布地奈德联合复方异丙托溴铵治疗小儿哮喘急性发作的临床效果观察[J].临床合理用药杂志，2019，12（32）：103-104.
[14]	杨赛花.雾化吸入可必特治疗慢性阻塞性肺疾病急性加重期的护理观察[J].实用临床护理学电子杂志，2019，4（41）：9.
[15]	胡云权.阿奇霉素序贯疗法与布地奈德和可必特雾化吸入对小儿支原体肺炎的疗效及其对肺功能指标的影响[J].抗感染药学，2019，16（6）：1012-1014.
[16]	季晓明.普米克令舒与可必特联合治疗哮喘性支气管炎患者的血气指标与临床疗效分析[J].当代医学，2020，26（14）：6-8.
[17]	叶永灿，黄少彬，吴童.干扰素联合高渗盐水对呼吸道合胞病毒肺炎患者临床症状及生化指标的影响[J].临床肺科杂志，2017，22（6）：1098-1100.
[18]	李林祖，黄诚花，梁秀琼，等.奥司他韦联合痰热清治疗呼吸道合胞病毒肺炎的有效性和安全性[J].中国医药导报，2017，14（9）：142-145.
[19]	王晶晶.阿奇霉素序贯疗法联合布地奈德、可必特雾化吸入对小儿支原体肺炎的疗效及其对NO 呼吸试验指标的影响[J].中国实用医药，2020，15（6）：126-128.